Shanghai Ruizhi Technology Co., Ltd. (Shanghai Ruizhi Technology) is a high-tech enterprise wholly owned by Shanghai Ruikang Biotechnology, focusing on the research and development, sales, and innovative services of clinical mass spectrometry technology and clinical mass spectrometry detection reagent products. It has a first-class and standardized mass spectrometry research and development laboratory, and has established subsidiaries and laboratories in Silicon Valley, USA. It gathers high-end talents at home and abroad, masters international leading technology, and carries out technology research and development and services for the advantages and needs of mass spectrometry technology applied to clinical precision detection. It has achieved remarkable research results in early screening and diagnosis of major diseases, drug concentration detection, steroid hormone detection, Alzheimer's disease detection, tuberculosis infectious disease detection, human comprehensive nutrition assessment, etc. It has applied for dozens of domestic and international patents, The number of Class II medical device product registration certificates obtained for clinical mass spectrometry detection kits is leading in the industry, with multiple clinical mass spectrometry detection kit products being domestically pioneering or exclusive.

Shanghai Ruiqi Medical Equipment Co., Ltd. (Shanghai Ruiqi Medical) is wholly owned by Shanghai Ruikang Biotechnology, specializing in third-party logistics distribution and services for medical testing, agency of clinical testing equipment and reagent consumables, and joint construction of large laboratories.

Business Area

1.Medical examination, third-party logistics and relevant services

Logistics distribution of IVD reagents and related consumables, information-based service for laboratory, related research collaboration. Provide professional outsourcing distribution services by service providers specializing in logistics and distribution other than hospitals and manufacturers. Undertake the long-term and stable supply and management services of all consumables in the hospital laboratory, providing the hospital with an efficient logistics distribution and management service model. This not only simplifies the hospital's procurement process, but also improves product quality and information service level and reduces the hospital's operating costs through centralized procurement and standardized management. Through the modernized ERP information system, hospitals are able to achieve instant ordering, viewing, acceptance and statistical functions, thus enhancing management efficiency. In addition, third-party logistics companies set up warehouses within hospitals to help hospitals realize zero inventory and reduce the risk of obsolescence and out-of-stock. This model also helps avoid legal and regulatory risks, as all registration certificates and licensing documents are filed in strict accordance with medical device regulations. It has been reported that 70% of hospitals in the US have adopted this model, and hundreds of hospitals in China have begun to try it. Practice has shown that with the adoption of third-party logistics and distribution, operational costs can be reduced by 60%, service levels can be improved by 60%, core business concentration can be increased by 56%, and the number of employees can be reduced by 40%, thus enabling hospitals to devote more resources and energy to the in-depth development of their specialty areas.

2.Distribution of clinical test equipment and reagent consumables

All kinds of equipment including large automatic biochemical analyzer, chemiluminescence inspection equipment, class III and class V blood count instruments and related components, consumables and reagents.

3.Building of district and above level hospitals’ central laboratories

Providing international advanced level of automated laboratory assembly line, advanced laboratory management system for making inspection data in high-mobility and self-management model, complete community, small, medium hospital laboratory specimen collection programs, regional inspection data management system to achieve the mutual recognition of inspection results, first-class inspection expert team in the project development, scientific research and other aspects of technical support, training, learning and exchange opportunities in relevant departments and laboratories of famous hospitals at home and abroad and assistance to hospital laboratories with ISO or CAP certification.

Professional Team

All the staff have university degree or above with have medical, biological, marketing management and other relevant professional background.

Core management personnel have many years of clinical testing equipment and reagent consumables marketing management experience, a number of international famous brand medical testing products successful agency experience and ability, rich team management experience and ability with a number of hospitals long-term good form of project cooperation experience, experience and strength.

Marketing Concept

Common development leads to mutual benefit.

Vision

To become a first-class service provider in the industry.

Quality Commitment

Domestic and abroad well-known manufacturers products, standardized, strict, ethical operation management system, ensuring that we provide every partner with fair, efficient, quality assurance solutions and quality assurance, which will always be improving.

Service Assurance

24 hours non-stop service, meet customer needs at any time.

Tianjin Ruibiao Biotechnology Co., Ltd. (Tianjin Ruibiao Biotechnology) is a high-tech enterprise specializing in the research and development, production, and sales of third-party quality control products, which is a subsidiary of Shanghai Ruikang Biotechnology Holdings.

Committed to providing high-quality quality control products with wide coverage, high flexibility, strong applicability, and excellent stability, while also providing professional consulting services for the ISO15189 quality management system. By building a one-stop medical laboratory quality service ecosystem, we aim to enhance the overall quality of medical diagnosis and treatment services.

Collaborating with renowned experts and professional laboratories both domestically and internationally, we have developed and produced quality control products that meet international standards, as well as first-class, standardized, and large-scale production facilities. We have a sound marketing network to provide users with better product and service experiences.

We will always adhere to the corporate purpose of "smart innovation technology, technology caring for health", follow the business philosophy of "quality-oriented, honest management, and enterprising", and provide assistance for the continuous improvement of laboratory quality control.

Having a mature business cooperation platform covering the whole country, we can sustainably provide high-quality products and excellent services, and are willing to work together with more ambitious individuals to create a win-win situation!

Ruizhi Technology Co., Ltd. (Ruizhi Technology) is wholly owned by Shanghai Ruizhi Technology and established in California, USA. It is an innovative enterprise focused on the development, sales, and service of precision medical diagnostic products. With clinical mass spectrometry as the core technology platform, we are committed to developing highly sensitive and accurate in vitro diagnostic products, aiming to promote the development of personalized medicine.

Focusing on addressing key needs in the field of clinical diagnosis, its product development covers multiple high impact disease areas such as neurodegenerative diseases, infectious diseases, and tumors, providing innovative solutions for clinical diagnosis. It has also established close partnerships with top universities and medical institutions in the United States, including Stanford University Hospital and the University of Michigan School of Medicine.

In addition, we not only provide high-quality products and services for North America, but also continuously explore markets in Asia, Australia, Europe, and other regions. In the future, we will further deepen our layout in the field of diagnosis and work with global partners to create a more accurate, efficient, and personalized new era of medical care.